Press Releases

To celebrate SKITTLES Littles, one lucky fan can now not only "Taste the Rainbow," but live in it too, in a space designed by interior decorator Dani Klarić.

NEWARK, N.J., April 30, 2024 /PRNewswire/ -- Mars' SKITTLES® is encouraging fans to live large in the littlest of spaces in honor of the recent launch of the brand's newest innovation, SKITTLES Littles. In celebration, SKITTLES is giving one lucky winner the chance to live in a mini-yet-maximalist,... (continue reading...)

Achieves FDA Approval for Sterile Injectable Drug Product Manufacturing

 FISHERS, Ind, April 30, 2024 /PRNewswire/ -- INCOG BioPharma Services proudly announces that its sterile injectable manufacturing facility has received approval from the U.S. Food and Drug Administration (FDA) to produce a commercially approved drug product. The regulatory approval for its customer signifies a significant milestone for INCOG, as it positions itself as an emerging leader in the... (continue reading...)

First customer sites include the University of Arkansas for Medical Sciences, MUSC Health, and Calif.-based Acacia Clinics and Kaizen Brain Center

BURLINGAME, Calif.--(BUSINESS WIRE)-- Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced the commercial launch of the SAINT® neuromodulation system, a groundbreaking, rapid-acting therapy for treatment-resistant major... (continue reading...)

Economic momentum cools as rates remain elevated

PROVIDENCE, R.I.--(BUSINESS WIRE)-- The national Citizens Business Conditions Index™ (CBCI) fell to 48.2 to start the year as business activity normalized from elevated levels in recent quarters. The reading below 50 indicates that economic momentum slowed during the first quarter against a backdrop of moderately restrictive monetary policy.

Labor markets and consumer trends remained resilient in the first... (continue reading...)

CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024

Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of neffy under NAC conditions and updated testing concerning nitrosamine levels

Exclusive licensing deal for Australia and New Zealand with CSL Seqirus; CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialization... (continue reading...)